Mark Rolfe
- Oncology top 1%
- Cancer-related Molecular Pathways 8
- Peptidase Inhibition and Analysis 5
- HER2/EGFR in Cancer Research 5
- Cell Biology top 1%
- Molecular Biology top 1%
- Ubiquitin and proteasome pathways 25
- Protein Degradation and Inhibitors 11
- Hematology top 2%
- Multiple Myeloma Research and Treatments 5
- Cancer Research top 5%
- NF-κB Signaling Pathways 6
-
- Chronic Lymphocytic Leukemia Research 6
- Co-authors
- Peggy Beer‐RomeroMichele PaganoAnne M. TheodorasGiulio DraettaSun W. TamGiannino Del SalP. Renée YewVincent Chau
- Partner nations
- United StatesUnited KingdomSpain
In The Last Decade
Mark Rolfe
53 papers receiving 5.9k citations
Hit Papers
Peers
Comparison fields: 5 of 124
- Oncology 2.5k
- Cell Biology 1.2k
- Molecular Biology 4.6k
- Hematology 471
- Cancer Research 570
Countries citing papers authored by Mark Rolfe
This map shows the geographic impact of Mark Rolfe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Rolfe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Rolfe more than expected).
Fields of papers citing papers by Mark Rolfe
This network shows the impact of papers produced by Mark Rolfe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Rolfe. The network helps show where Mark Rolfe may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Mark Rolfe, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2021 | 12 | |
| 2 | 2021 | 4 | |
| 3 | 2010 | 409 | |
| 4 | 2010 | 188 | |
| 5 | 2009 | 16 | |
| 6 | Discovery of MLN4924, a Novel, First in Class Nedd8 Activating Enzyme Inhibitor for the Treatment of Cancer | 2007 | 1 |
| 7 | 2006 | 57 | |
| 8 | 2006 | 88 | |
| 9 | Drug discovery in the ubiquitin–proteasome systembreakdown → | 2006 | 503 |
| 10 | 2006 | 14 | |
| 11 | 2004 | 24 | |
| 12 | 2003 | 63 | |
| 13 | 2003 | 37 | |
| 14 | 2002 | 23 | |
| 15 | 2001 | 65 | |
| 16 | 2000 | 33 | |
| 17 | 1997 | 88 | |
| 18 | 1997 | 91 | |
| 19 | A 20s complex containing CDC27 and CDC16 catalyzes the mitosis-specific conjugation of ubiquitin to cyclin Bbreakdown → | 1995 | 826 |
| 20 | 1995 | 12 |
About Mark Rolfe
Mark Rolfe is a scholar working on Microbiology, Oncology, Genetics, Molecular Biology and Hematology, having authored 55 papers that have together received 6.0k indexed citations. Recurring topics across this work include Ubiquitin and proteasome pathways (25 papers), Protein Degradation and Inhibitors (11 papers), Cancer-related Molecular Pathways (8 papers), Chronic Lymphocytic Leukemia Research (6 papers), NF-κB Signaling Pathways (6 papers), Multiple Myeloma Research and Treatments (5 papers), Peptidase Inhibition and Analysis (5 papers) and HER2/EGFR in Cancer Research (5 papers). The work is most often cited by research in Oncology (2.5k citations), Cell Biology (1.2k citations), Molecular Biology (4.6k citations), Hematology (471 citations) and Cancer Research (570 citations). Mark Rolfe has collaborated with scholars based in United States, United Kingdom and Spain. Frequent co-authors include Peggy Beer‐Romero, Michele Pagano, Anne M. Theodoras, Giulio Draetta, Sun W. Tam, Giannino Del Sal, P. Renée Yew, Vincent Chau, Grzegorz Nalepa and J. Wade Harper. Their work appears in journals such as Blood, Cancer Research, Molecular Cancer Therapeutics, American Journal of Clinical Pathology and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.